BOC International has released a research report stating that the recent approval by the National Medical Products Administration (NMPA) of Borui Kang's implantable brain-computer interface (BCI) system for hand motor function compensation marks the world's first launch of such a product. This signifies that China's BCI industry is transitioning from "technical validation" to "commercial implementation." Currently, non-invasive BCI technology, with its advantages of high safety and low cost, is being adopted first in rehabilitation and consumer scenarios. Invasive technology is gradually achieving clinical progress in high-value medical applications. With the launch of related core products, the BCI industry is entering a critical phase of moving from technological exploration to large-scale commercial application, indicating substantial future growth potential. The main points from BOC International are as follows:
The approval of the first invasive BCI product establishes a new era of commercialization. Borui Kang's product consists of a BCI implant, an implantable EEG electrode kit, an EEG signal transceiver, a pneumatic glove device, a disposable surgical tool kit, EEG decoding software, medical testing software, and clinical management software. It is intended for patients with quadriplegia caused by cervical spinal cord injury, assisting in the compensation of hand grasping function through the pneumatic glove device. The product utilizes minimally invasive epidural implantation and wireless power and communication technology. Clinical trial results show that subjects achieved significant improvement in hand grasping ability using the product, thereby enhancing their quality of life. The approval of Borui Kang's implantable BCI product marks the official entry of the world's first invasive BCI medical device into the clinical application stage, representing a milestone event for China's BCI industry as it moves from "technical validation" to "commercial implementation."
Policy support continues to intensify, bringing developmental benefits to the BCI industry. In the recent draft outline for the "15th Five-Year Plan," brain-computer interfaces were explicitly listed as one of the key future industries targeted for national cultivation, setting a strategic development direction. Since 2025, multiple policies have been implemented: seven ministries, including the Ministry of Industry and Information Technology, issued the "Implementation Opinions on Promoting the Innovative Development of the Brain-Computer Interface Industry"; the NMPA approved and released China's first BCI medical device standard; and the National Healthcare Security Administration established new pricing items related to BCI, clarifying the basis for charges. On December 24, 2025, the NMPA included "implantable brain-computer interface medical devices" in the "Catalog of High-End Medical Devices for Priority Review." The approval of Borui Kang's product is a practical reflection of this innovative medical device priority review policy. The effects of this comprehensive policy approach—from top-level industrial direction-setting to accelerated approvals and the implementation of hospital charging items—are gradually becoming apparent, accelerating the commercialization process of the BCI industry.
The brain-computer interface market has broad prospects and significant growth potential. According to data from Fortune Business Insights, the global BCI market size was approximately $240 million in 2025 and is projected to grow to $960 million by 2034, with a compound annual growth rate (CAGR) of about 15.9% from 2026 to 2034. In the Chinese market, data from the Zhongshang Industrial Research Institute shows that China's BCI market size was 3.2 billion yuan in 2024, a year-on-year increase of 18.81%, and is expected to reach 4.6 billion yuan by 2026. Currently, non-invasive BCI technology is being adopted first in rehabilitation and consumer scenarios due to its safety and cost advantages, while invasive technology is making gradual clinical progress in high-value medical applications. With the launch of related core products, the BCI industry is entering a critical phase of moving from technological exploration to large-scale commercial application, indicating substantial future growth potential.
Investment Recommendation: With the approval of the world's first invasive product, the domestic BCI industry has entered a period of commercial validation. It is recommended to focus on companies related to brain-computer interfaces, such as Innovative Medical Management Co.,Ltd. (002173.SZ), Mehow Innovative Ltd. (301363.SZ), Xiangyu Medical Co.,Ltd. (688626.SH), Jiangsu Apon Medical Technology Co.,Ltd. (300753.SZ), Cofoe Medical Technology Co.,Ltd. (301087.SZ), Nanjing Medlander Medical Technology Co.,Ltd. (688273.SH), Nanjing Vishee Medical Technology Co.,Ltd. (688580.SH), and Sanbo Hospital Management Group Limited (301293.SZ).
Risk Factors: Risks related to slower-than-expected commercial promotion: In the initial stages after a new product's launch, factors such as physician training, hospital adoption, and patient affordability may cause product uptake to be slower than anticipated. Risks related to long-term safety and stability: After market launch, the product's long-term safety and stability still need to be validated through large-scale application.
Comments